Shares of Laurus Labs Ltd plunged 15 per cent in Monday's trade amid reports the US State Department issued a 'stop-work' order for all existing foreign assistance, which also impacted ...

Generic drugmaker Laurus Labs’ consolidated net profit rose to ₹90.61 crore in the third quarter ended December from ₹25.17 crore year earlier on a 18% increase in revenue from operations at ...

Laurus Labs shares plunged 15 per cent on January 27 as investors locked in profits, ending the stock's two-day winning streak. The stock had risen nearly 6% over the past two sessions, driven by ...

Shares of Laurus Labs tanked 14 percent on January 27 as investors rushed to book profits off the stock, thereby snapping its two-day winning run. The stock gained nearly 6 percent in the past ...

The uniforms are very similar to the ones the team previously wore, but they have changed up the piping patters and removed the white piping around the buttons. Phil Hecken of "Uni-Watch" also ...

Indian benchmark indices managed to settle with decent gains, following a volatile trading session, on the back of strength in the banking stocks. BSE Sensex jumped 566.63 points, or 0.75 per cent ...

Laurus Labs share slipped 15 per cent at Rs 510.60 a piece on the BSE in Monday’s intraday trade. This came after analysts post the Q3FY25 results reckoned that the company’s valuation is at a premium ...

Laurus Labs Ltd. has issued a clarification to the exchanges on Monday, January 27, in response to the reports of US President Donald Trump freezing Emergency funding for AIDS relief for at least 90 ...

Laurus Labs reported a 7% YoY drop in API revenues to Rs 531 crore for Q3 FY24, driven by lower ARV volumes. However, the FDF segment saw ARV sales grow 40% sequentially, highlighting a rebound in ...

Shares of Laurus Labs Ltd. surged on Friday, January 22, after the company's December quarter results were better than expectations. The company's Earnings Before Interest, Tax, Depreciation and ...

Laurus Labs (CMP: Rs 603; Market cap: Rs 32,492 crore; Rating: Overweight) posted strong results in Q3FY25, led by a ramp-up in the CDMO (Contract Development and Manufacturing Organisation) business.